Last reviewed · How we verify
Azilsartan Medoxomil Low-dose
Azilsartan Medoxomil Low-dose is a Angiotensin II receptor blocker (ARB) Small molecule drug developed by Arbor Pharmaceuticals, Inc.. It is currently in Phase 3 development for Hypertension. Also known as: AR14, AZM-L.
Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors to reduce blood pressure.
Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors to reduce blood pressure. Used for Hypertension.
At a glance
| Generic name | Azilsartan Medoxomil Low-dose |
|---|---|
| Also known as | AR14, AZM-L |
| Sponsor | Arbor Pharmaceuticals, Inc. |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Azilsartan medoxomil is a prodrug that is hydrolyzed to azilsartan, which competitively antagonizes angiotensin II type 1 (AT1) receptors on vascular smooth muscle and other tissues. By blocking AT1 receptor signaling, it prevents vasoconstriction and aldosterone secretion, leading to vasodilation and reduced sodium retention, thereby lowering blood pressure. The low-dose formulation provides a reduced therapeutic dose for patients requiring lower antihypertensive exposure.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Diarrhea
- Hypotension
Key clinical trials
- An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension (PHASE3)
- Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azilsartan Medoxomil Low-dose CI brief — competitive landscape report
- Azilsartan Medoxomil Low-dose updates RSS · CI watch RSS
- Arbor Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Azilsartan Medoxomil Low-dose
What is Azilsartan Medoxomil Low-dose?
How does Azilsartan Medoxomil Low-dose work?
What is Azilsartan Medoxomil Low-dose used for?
Who makes Azilsartan Medoxomil Low-dose?
Is Azilsartan Medoxomil Low-dose also known as anything else?
What drug class is Azilsartan Medoxomil Low-dose in?
What development phase is Azilsartan Medoxomil Low-dose in?
What are the side effects of Azilsartan Medoxomil Low-dose?
What does Azilsartan Medoxomil Low-dose target?
Related
- Drug class: All Angiotensin II receptor blocker (ARB) drugs
- Target: All drugs targeting AT1 receptor (Angiotensin II type 1 receptor)
- Manufacturer: Arbor Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Also known as: AR14, AZM-L
- Compare: Azilsartan Medoxomil Low-dose vs similar drugs
- Pricing: Azilsartan Medoxomil Low-dose cost, discount & access